AstraZeneca has reportedly made a non-binding offer worth approximately $10 billion to acquire Rhythm Pharmaceuticals, a US-based biotechnology company specialising in treatments for rare metabolic disorders and severe obesity.
The reported AstraZeneca Rhythm Pharmaceuticals acquisition could strengthen the British pharmaceutical company’s presence in the growing obesity treatment market while expanding its rare-disease portfolio. However, neither company has publicly confirmed an agreement, and it’s a non-binding proposal.
More Details On AstraZeneca Rhythm Pharmaceuticals Acquisition Offer
The reported Rhythm Pharmaceuticals takeover follows an earlier offer of $124 per share, which The Wall Street Journal said AstraZeneca made last month. Also reports said that the company had proposed as much as $134 per share, including milestone-based payments.
The news triggered a strong market reaction. Rhythm Pharmaceuticals shares closed at $110.68 on November 4, rising 28% in one trading session. This gave the company a market capitalisation of approximately $7.64 billion.
Significance of AstraZeneca Rhythm Pharmaceuticals Acquisition
Rhythm Pharmaceuticals develops treatments for rare neuroendocrine and metabolic disorders. These conditions can affect the body’s ability to regulate hunger, appetite, and body weight, sometimes resulting in severe obesity.
Its specialised focus makes the company a potential strategic addition to AstraZeneca’s obesity drug strategy. Unlike widely used weight-management medicines, Rhythm’s treatments target specific biological pathways involved in rare genetic and acquired forms of obesity.
The Rhythm Pharmaceuticals acquisition could give AstraZeneca an established commercial presence in this specialised treatment segment, alongside access to existing medicines and experimental drug candidates.
Rhythm’s IMCIVREE Strengthens AstraZeneca’s Rare Disease Portfolio
Rhythm’s leading medicine, IMCIVREE (setmelanotide), is an important part of its commercial business. The treatment is approved in the United States, Europe, and other markets for certain rare conditions, including Bardet-Biedl syndrome, specific genetic deficiencies, and acquired hypothalamic obesity.
In March 2026, the US Food and Drug Administration (FDA) expanded IMCIVREE’s use to include acquired hypothalamic obesity. It became the first FDA-approved treatment for this condition in the United States.
Rhythm’s commercial performance also highlights the opportunity. In its November 3, 2026, third-quarter results, the company reported $92.1 million in global IMCIVREE revenue, representing a 29% increase from the previous quarter. It had also received more than 700 patient start forms for acquired hypothalamic obesity treatment by September 30.
Rhythm’s Drug Pipeline Adds to the Acquisition Opportunity
Beyond IMCIVREE, Rhythm is developing additional treatments for rare metabolic and neuroendocrine conditions.
Its pipeline includes:
- Bivamelagon: An oral drug candidate licensed from LG Chem, being advanced towards pivotal-stage development for acquired hypothalamic obesity and Prader-Willi syndrome.
- RM-718: An investigational weekly injectable treatment in early clinical development.
- Congenital hyperinsulinism programmes: Preclinical research targeting a rare condition that causes excessive insulin production and dangerously low blood sugar.
These programmes could provide AstraZeneca with further opportunities to develop specialised treatments if the proposed Rhythm Pharmaceuticals acquisition offer moves forward.
Rhythm Pharmaceuticals Takeover Fits AstraZeneca’s Strategy
AstraZeneca would reportedly pursue the Rhythm Pharmaceuticals acquisition offer through Alexion, its rare-disease business. The company acquired Alexion for approximately $39 billion in 2021 to expand beyond its established oncology and biopharmaceutical businesses.
Since then, Alexion has become a central part of AstraZeneca’s efforts to strengthen its position in specialised medicines.
Adding Rhythm could complement these activities by giving AstraZeneca access to treatments targeting rare forms of obesity rather than relying exclusively on broader weight-management approaches.
Next Step in AstraZeneca Rhythm Pharmaceuticals Acquisition
The reported AstraZeneca Rhythm Pharmaceuticals acquisition remains at the proposal stage. The companies have not announced a definitive agreement, and the status of negotiations and Rhythm’s response remain unclear. Until then, the reported $10 billion offer should be viewed as a potential acquisition rather than a completed deal.
